nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylephrine—CYP1A2—type 2 diabetes mellitus	0.334	1	CbGaD
Phenylephrine—ADRA1D—Bromocriptine—type 2 diabetes mellitus	0.12	0.304	CbGbCtD
Phenylephrine—ADRA1B—Bromocriptine—type 2 diabetes mellitus	0.0875	0.221	CbGbCtD
Phenylephrine—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0691	0.175	CbGbCtD
Phenylephrine—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.0391	0.0987	CbGbCtD
Phenylephrine—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.0308	0.0777	CbGbCtD
Phenylephrine—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.0291	0.0735	CbGbCtD
Phenylephrine—CYP1A2—Losartan—type 2 diabetes mellitus	0.0198	0.0501	CbGbCtD
Phenylephrine—Isoprenaline—PIK3R1—type 2 diabetes mellitus	0.00171	0.354	CrCbGaD
Phenylephrine—Isoprenaline—ADRB3—type 2 diabetes mellitus	0.000617	0.128	CrCbGaD
Phenylephrine—Norepinephrine—ADRB3—type 2 diabetes mellitus	0.000571	0.119	CrCbGaD
Phenylephrine—Epinephrine—ADRB3—type 2 diabetes mellitus	0.000518	0.108	CrCbGaD
Phenylephrine—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.000261	0.00152	CcSEcCtD
Phenylephrine—Urticaria—Pioglitazone—type 2 diabetes mellitus	0.000261	0.00151	CcSEcCtD
Phenylephrine—Headache—Repaglinide—type 2 diabetes mellitus	0.00026	0.00151	CcSEcCtD
Phenylephrine—Shock—Glyburide—type 2 diabetes mellitus	0.00026	0.00151	CcSEcCtD
Phenylephrine—Paraesthesia—Bromocriptine—type 2 diabetes mellitus	0.000259	0.0015	CcSEcCtD
Phenylephrine—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000259	0.0015	CcSEcCtD
Phenylephrine—Cardiac disorder—Metformin—type 2 diabetes mellitus	0.000259	0.0015	CcSEcCtD
Phenylephrine—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.000259	0.0015	CcSEcCtD
Phenylephrine—Sweating increased—Ramipril—type 2 diabetes mellitus	0.000259	0.0015	CcSEcCtD
Phenylephrine—Norepinephrine—ADRA2A—type 2 diabetes mellitus	0.000259	0.0537	CrCbGaD
Phenylephrine—Dysgeusia—Orlistat—type 2 diabetes mellitus	0.000258	0.0015	CcSEcCtD
Phenylephrine—Dyspnoea—Bromocriptine—type 2 diabetes mellitus	0.000257	0.00149	CcSEcCtD
Phenylephrine—Palpitations—Gliclazide—type 2 diabetes mellitus	0.000257	0.00149	CcSEcCtD
Phenylephrine—Loss of consciousness—Gliclazide—type 2 diabetes mellitus	0.000255	0.00148	CcSEcCtD
Phenylephrine—Hyperhidrosis—Glyburide—type 2 diabetes mellitus	0.000255	0.00148	CcSEcCtD
Phenylephrine—Urticaria—Glimepiride—type 2 diabetes mellitus	0.000254	0.00148	CcSEcCtD
Phenylephrine—Visual impairment—Irbesartan—type 2 diabetes mellitus	0.000254	0.00147	CcSEcCtD
Phenylephrine—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.000253	0.00147	CcSEcCtD
Phenylephrine—Angiopathy—Metformin—type 2 diabetes mellitus	0.000253	0.00147	CcSEcCtD
Phenylephrine—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.000253	0.00147	CcSEcCtD
Phenylephrine—Immune system disorder—Metformin—type 2 diabetes mellitus	0.000252	0.00146	CcSEcCtD
Phenylephrine—Mediastinal disorder—Metformin—type 2 diabetes mellitus	0.000252	0.00146	CcSEcCtD
Phenylephrine—Vision blurred—Valsartan—type 2 diabetes mellitus	0.000251	0.00146	CcSEcCtD
Phenylephrine—Hypertension—Gliclazide—type 2 diabetes mellitus	0.000251	0.00145	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000249	0.00145	CcSEcCtD
Phenylephrine—Vision blurred—Orlistat—type 2 diabetes mellitus	0.000248	0.00144	CcSEcCtD
Phenylephrine—Chest pain—Gliclazide—type 2 diabetes mellitus	0.000247	0.00143	CcSEcCtD
Phenylephrine—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000247	0.00143	CcSEcCtD
Phenylephrine—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000247	0.00143	CcSEcCtD
Phenylephrine—Nausea—Repaglinide—type 2 diabetes mellitus	0.000246	0.00143	CcSEcCtD
Phenylephrine—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.000246	0.00142	CcSEcCtD
Phenylephrine—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000245	0.00142	CcSEcCtD
Phenylephrine—Cardiac disorder—Irbesartan—type 2 diabetes mellitus	0.000244	0.00142	CcSEcCtD
Phenylephrine—Pruritus—Glipizide—type 2 diabetes mellitus	0.000243	0.00141	CcSEcCtD
Phenylephrine—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.000242	0.0014	CcSEcCtD
Phenylephrine—Syncope—Valsartan—type 2 diabetes mellitus	0.000239	0.00139	CcSEcCtD
Phenylephrine—Angiopathy—Irbesartan—type 2 diabetes mellitus	0.000239	0.00139	CcSEcCtD
Phenylephrine—Salbutamol—CYP3A4—type 2 diabetes mellitus	0.000239	0.0495	CrCbGaD
Phenylephrine—Dysgeusia—Metformin—type 2 diabetes mellitus	0.000238	0.00138	CcSEcCtD
Phenylephrine—Immune system disorder—Irbesartan—type 2 diabetes mellitus	0.000238	0.00138	CcSEcCtD
Phenylephrine—Mediastinal disorder—Irbesartan—type 2 diabetes mellitus	0.000237	0.00138	CcSEcCtD
Phenylephrine—Paraesthesia—Glyburide—type 2 diabetes mellitus	0.000237	0.00138	CcSEcCtD
Phenylephrine—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000236	0.00137	CcSEcCtD
Phenylephrine—Palpitations—Valsartan—type 2 diabetes mellitus	0.000236	0.00137	CcSEcCtD
Phenylephrine—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.000235	0.00137	CcSEcCtD
Phenylephrine—Arrhythmia—Irbesartan—type 2 diabetes mellitus	0.000235	0.00137	CcSEcCtD
Phenylephrine—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000235	0.00136	CcSEcCtD
Phenylephrine—Epinephrine—ADRA2A—type 2 diabetes mellitus	0.000235	0.0487	CrCbGaD
Phenylephrine—Loss of consciousness—Valsartan—type 2 diabetes mellitus	0.000235	0.00136	CcSEcCtD
Phenylephrine—Acute coronary syndrome—Ramipril—type 2 diabetes mellitus	0.000233	0.00135	CcSEcCtD
Phenylephrine—Palpitations—Orlistat—type 2 diabetes mellitus	0.000233	0.00135	CcSEcCtD
Phenylephrine—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000233	0.00135	CcSEcCtD
Phenylephrine—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000232	0.00135	CcSEcCtD
Phenylephrine—Myocardial infarction—Ramipril—type 2 diabetes mellitus	0.000232	0.00135	CcSEcCtD
Phenylephrine—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000231	0.00134	CcSEcCtD
Phenylephrine—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.00023	0.00134	CcSEcCtD
Phenylephrine—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.000229	0.00133	CcSEcCtD
Phenylephrine—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	0.000229	0.00133	CcSEcCtD
Phenylephrine—Vision blurred—Metformin—type 2 diabetes mellitus	0.000229	0.00133	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000228	0.00132	CcSEcCtD
Phenylephrine—Tremor—Metformin—type 2 diabetes mellitus	0.000228	0.00132	CcSEcCtD
Phenylephrine—Chest pain—Valsartan—type 2 diabetes mellitus	0.000227	0.00132	CcSEcCtD
Phenylephrine—Dizziness—Glipizide—type 2 diabetes mellitus	0.000227	0.00132	CcSEcCtD
Phenylephrine—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000226	0.00131	CcSEcCtD
Phenylephrine—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000226	0.00131	CcSEcCtD
Phenylephrine—Tension—Irbesartan—type 2 diabetes mellitus	0.000225	0.00131	CcSEcCtD
Phenylephrine—Angiopathy—Losartan—type 2 diabetes mellitus	0.000225	0.0013	CcSEcCtD
Phenylephrine—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.000225	0.0013	CcSEcCtD
Phenylephrine—Chest pain—Orlistat—type 2 diabetes mellitus	0.000224	0.0013	CcSEcCtD
Phenylephrine—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000223	0.00129	CcSEcCtD
Phenylephrine—Nervousness—Irbesartan—type 2 diabetes mellitus	0.000223	0.00129	CcSEcCtD
Phenylephrine—Epinephrine—TNF—type 2 diabetes mellitus	0.000222	0.0461	CrCbGaD
Phenylephrine—Arrhythmia—Losartan—type 2 diabetes mellitus	0.000221	0.00128	CcSEcCtD
Phenylephrine—Vomiting—Glipizide—type 2 diabetes mellitus	0.000218	0.00127	CcSEcCtD
Phenylephrine—Syncope—Metformin—type 2 diabetes mellitus	0.000218	0.00126	CcSEcCtD
Phenylephrine—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000217	0.00126	CcSEcCtD
Phenylephrine—Rash—Glipizide—type 2 diabetes mellitus	0.000216	0.00125	CcSEcCtD
Phenylephrine—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000216	0.00125	CcSEcCtD
Phenylephrine—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000216	0.00125	CcSEcCtD
Phenylephrine—Headache—Glipizide—type 2 diabetes mellitus	0.000215	0.00125	CcSEcCtD
Phenylephrine—Tremor—Irbesartan—type 2 diabetes mellitus	0.000215	0.00125	CcSEcCtD
Phenylephrine—Palpitations—Metformin—type 2 diabetes mellitus	0.000215	0.00125	CcSEcCtD
Phenylephrine—Shock—Valsartan—type 2 diabetes mellitus	0.000214	0.00124	CcSEcCtD
Phenylephrine—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.000214	0.00124	CcSEcCtD
Phenylephrine—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000214	0.00124	CcSEcCtD
Phenylephrine—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.000213	0.00123	CcSEcCtD
Phenylephrine—Tension—Losartan—type 2 diabetes mellitus	0.000212	0.00123	CcSEcCtD
Phenylephrine—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000212	0.00123	CcSEcCtD
Phenylephrine—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000212	0.00123	CcSEcCtD
Phenylephrine—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000211	0.00123	CcSEcCtD
Phenylephrine—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000211	0.00123	CcSEcCtD
Phenylephrine—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000211	0.00122	CcSEcCtD
Phenylephrine—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000211	0.00122	CcSEcCtD
Phenylephrine—Agitation—Irbesartan—type 2 diabetes mellitus	0.000211	0.00122	CcSEcCtD
Phenylephrine—Hypertension—Metformin—type 2 diabetes mellitus	0.00021	0.00122	CcSEcCtD
Phenylephrine—Urticaria—Glyburide—type 2 diabetes mellitus	0.00021	0.00122	CcSEcCtD
Phenylephrine—Nervousness—Losartan—type 2 diabetes mellitus	0.00021	0.00122	CcSEcCtD
Phenylephrine—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000209	0.00121	CcSEcCtD
Phenylephrine—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.000208	0.00121	CcSEcCtD
Phenylephrine—Chest pain—Metformin—type 2 diabetes mellitus	0.000207	0.0012	CcSEcCtD
Phenylephrine—Headache—Pioglitazone—type 2 diabetes mellitus	0.000206	0.00119	CcSEcCtD
Phenylephrine—Syncope—Irbesartan—type 2 diabetes mellitus	0.000206	0.00119	CcSEcCtD
Phenylephrine—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000205	0.00119	CcSEcCtD
Phenylephrine—Visual impairment—Ramipril—type 2 diabetes mellitus	0.000205	0.00119	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000205	0.00119	CcSEcCtD
Phenylephrine—Nausea—Glipizide—type 2 diabetes mellitus	0.000204	0.00118	CcSEcCtD
Phenylephrine—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000204	0.00118	CcSEcCtD
Phenylephrine—Vision blurred—Losartan—type 2 diabetes mellitus	0.000203	0.00118	CcSEcCtD
Phenylephrine—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000203	0.00118	CcSEcCtD
Phenylephrine—Pain—Gliclazide—type 2 diabetes mellitus	0.000203	0.00118	CcSEcCtD
Phenylephrine—Tremor—Losartan—type 2 diabetes mellitus	0.000202	0.00117	CcSEcCtD
Phenylephrine—Rash—Glimepiride—type 2 diabetes mellitus	0.000202	0.00117	CcSEcCtD
Phenylephrine—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000202	0.00117	CcSEcCtD
Phenylephrine—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.000202	0.00117	CcSEcCtD
Phenylephrine—Rash—Sitagliptin—type 2 diabetes mellitus	0.000201	0.00117	CcSEcCtD
Phenylephrine—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000201	0.00117	CcSEcCtD
Phenylephrine—Headache—Glimepiride—type 2 diabetes mellitus	0.000201	0.00116	CcSEcCtD
Phenylephrine—Headache—Sitagliptin—type 2 diabetes mellitus	0.0002	0.00116	CcSEcCtD
Phenylephrine—Agitation—Losartan—type 2 diabetes mellitus	0.000198	0.00115	CcSEcCtD
Phenylephrine—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000198	0.00115	CcSEcCtD
Phenylephrine—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000196	0.00113	CcSEcCtD
Phenylephrine—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000195	0.00113	CcSEcCtD
Phenylephrine—Shock—Metformin—type 2 diabetes mellitus	0.000195	0.00113	CcSEcCtD
Phenylephrine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000194	0.00113	CcSEcCtD
Phenylephrine—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000194	0.00113	CcSEcCtD
Phenylephrine—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000194	0.00113	CcSEcCtD
Phenylephrine—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000194	0.00112	CcSEcCtD
Phenylephrine—Syncope—Losartan—type 2 diabetes mellitus	0.000194	0.00112	CcSEcCtD
Phenylephrine—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000193	0.00112	CcSEcCtD
Phenylephrine—Skin disorder—Metformin—type 2 diabetes mellitus	0.000193	0.00112	CcSEcCtD
Phenylephrine—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000192	0.00111	CcSEcCtD
Phenylephrine—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000192	0.00111	CcSEcCtD
Phenylephrine—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000192	0.00111	CcSEcCtD
Phenylephrine—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000191	0.00111	CcSEcCtD
Phenylephrine—Palpitations—Losartan—type 2 diabetes mellitus	0.000191	0.00111	CcSEcCtD
Phenylephrine—Nausea—Glimepiride—type 2 diabetes mellitus	0.00019	0.0011	CcSEcCtD
Phenylephrine—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.00019	0.0011	CcSEcCtD
Phenylephrine—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.00019	0.0011	CcSEcCtD
Phenylephrine—Nausea—Sitagliptin—type 2 diabetes mellitus	0.00019	0.0011	CcSEcCtD
Phenylephrine—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000188	0.00109	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000188	0.00109	CcSEcCtD
Phenylephrine—Pruritus—Glyburide—type 2 diabetes mellitus	0.000187	0.00108	CcSEcCtD
Phenylephrine—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000186	0.00108	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000186	0.00108	CcSEcCtD
Phenylephrine—Shock—Irbesartan—type 2 diabetes mellitus	0.000184	0.00107	CcSEcCtD
Phenylephrine—Pain—Orlistat—type 2 diabetes mellitus	0.000184	0.00107	CcSEcCtD
Phenylephrine—Chest pain—Losartan—type 2 diabetes mellitus	0.000184	0.00107	CcSEcCtD
Phenylephrine—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000184	0.00107	CcSEcCtD
Phenylephrine—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000184	0.00106	CcSEcCtD
Phenylephrine—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000183	0.00106	CcSEcCtD
Phenylephrine—Rash—Bromocriptine—type 2 diabetes mellitus	0.000182	0.00106	CcSEcCtD
Phenylephrine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000182	0.00106	CcSEcCtD
Phenylephrine—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000182	0.00105	CcSEcCtD
Phenylephrine—Tension—Ramipril—type 2 diabetes mellitus	0.000182	0.00105	CcSEcCtD
Phenylephrine—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000181	0.00105	CcSEcCtD
Phenylephrine—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000181	0.00105	CcSEcCtD
Phenylephrine—Headache—Bromocriptine—type 2 diabetes mellitus	0.000181	0.00105	CcSEcCtD
Phenylephrine—Nervousness—Ramipril—type 2 diabetes mellitus	0.00018	0.00104	CcSEcCtD
Phenylephrine—Norepinephrine—CYP1A2—type 2 diabetes mellitus	0.00018	0.0373	CrCbGaD
Phenylephrine—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000178	0.00103	CcSEcCtD
Phenylephrine—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000177	0.00103	CcSEcCtD
Phenylephrine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000175	0.00101	CcSEcCtD
Phenylephrine—Tremor—Ramipril—type 2 diabetes mellitus	0.000173	0.00101	CcSEcCtD
Phenylephrine—Shock—Losartan—type 2 diabetes mellitus	0.000173	0.00101	CcSEcCtD
Phenylephrine—Urticaria—Valsartan—type 2 diabetes mellitus	0.000173	0.001	CcSEcCtD
Phenylephrine—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000173	0.001	CcSEcCtD
Phenylephrine—Tachycardia—Losartan—type 2 diabetes mellitus	0.000172	0.000997	CcSEcCtD
Phenylephrine—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000172	0.000995	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000171	0.000993	CcSEcCtD
Phenylephrine—Urticaria—Orlistat—type 2 diabetes mellitus	0.000171	0.000992	CcSEcCtD
Phenylephrine—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.00017	0.000988	CcSEcCtD
Phenylephrine—Agitation—Ramipril—type 2 diabetes mellitus	0.00017	0.000987	CcSEcCtD
Phenylephrine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000168	0.000975	CcSEcCtD
Phenylephrine—Vomiting—Glyburide—type 2 diabetes mellitus	0.000168	0.000974	CcSEcCtD
Phenylephrine—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000168	0.000973	CcSEcCtD
Phenylephrine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000167	0.000968	CcSEcCtD
Phenylephrine—Rash—Glyburide—type 2 diabetes mellitus	0.000166	0.000966	CcSEcCtD
Phenylephrine—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000166	0.000965	CcSEcCtD
Phenylephrine—Syncope—Ramipril—type 2 diabetes mellitus	0.000166	0.000963	CcSEcCtD
Phenylephrine—Headache—Glyburide—type 2 diabetes mellitus	0.000165	0.000959	CcSEcCtD
Phenylephrine—Palpitations—Ramipril—type 2 diabetes mellitus	0.000164	0.000949	CcSEcCtD
Phenylephrine—Epinephrine—CYP1A2—type 2 diabetes mellitus	0.000163	0.0338	CrCbGaD
Phenylephrine—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000163	0.000944	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000162	0.000937	CcSEcCtD
Phenylephrine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.00016	0.000931	CcSEcCtD
Phenylephrine—Pain—Irbesartan—type 2 diabetes mellitus	0.00016	0.000928	CcSEcCtD
Phenylephrine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000159	0.00092	CcSEcCtD
Phenylephrine—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000158	0.000918	CcSEcCtD
Phenylephrine—Urticaria—Metformin—type 2 diabetes mellitus	0.000158	0.000914	CcSEcCtD
Phenylephrine—Chest pain—Ramipril—type 2 diabetes mellitus	0.000158	0.000914	CcSEcCtD
Phenylephrine—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000157	0.000911	CcSEcCtD
Phenylephrine—Nausea—Glyburide—type 2 diabetes mellitus	0.000157	0.00091	CcSEcCtD
Phenylephrine—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000157	0.000909	CcSEcCtD
Phenylephrine—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000156	0.000908	CcSEcCtD
Phenylephrine—Pruritus—Valsartan—type 2 diabetes mellitus	0.000154	0.000894	CcSEcCtD
Phenylephrine—Pruritus—Orlistat—type 2 diabetes mellitus	0.000152	0.000883	CcSEcCtD
Phenylephrine—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000151	0.000874	CcSEcCtD
Phenylephrine—Pain—Losartan—type 2 diabetes mellitus	0.000151	0.000874	CcSEcCtD
Phenylephrine—Rash—Gliclazide—type 2 diabetes mellitus	0.000149	0.000867	CcSEcCtD
Phenylephrine—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000149	0.000866	CcSEcCtD
Phenylephrine—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000149	0.000863	CcSEcCtD
Phenylephrine—Shock—Ramipril—type 2 diabetes mellitus	0.000149	0.000862	CcSEcCtD
Phenylephrine—Headache—Gliclazide—type 2 diabetes mellitus	0.000148	0.000861	CcSEcCtD
Phenylephrine—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000148	0.000859	CcSEcCtD
Phenylephrine—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000147	0.000855	CcSEcCtD
Phenylephrine—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000147	0.000851	CcSEcCtD
Phenylephrine—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000146	0.000847	CcSEcCtD
Phenylephrine—Dizziness—Valsartan—type 2 diabetes mellitus	0.000144	0.000835	CcSEcCtD
Phenylephrine—Dizziness—Orlistat—type 2 diabetes mellitus	0.000142	0.000826	CcSEcCtD
Phenylephrine—Nausea—Gliclazide—type 2 diabetes mellitus	0.000141	0.000817	CcSEcCtD
Phenylephrine—Pruritus—Metformin—type 2 diabetes mellitus	0.00014	0.000814	CcSEcCtD
Phenylephrine—Urticaria—Losartan—type 2 diabetes mellitus	0.00014	0.000812	CcSEcCtD
Phenylephrine—Vomiting—Valsartan—type 2 diabetes mellitus	0.000138	0.000803	CcSEcCtD
Phenylephrine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000138	0.0008	CcSEcCtD
Phenylephrine—Rash—Valsartan—type 2 diabetes mellitus	0.000137	0.000797	CcSEcCtD
Phenylephrine—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000137	0.000796	CcSEcCtD
Phenylephrine—Vomiting—Orlistat—type 2 diabetes mellitus	0.000137	0.000794	CcSEcCtD
Phenylephrine—Headache—Valsartan—type 2 diabetes mellitus	0.000136	0.000791	CcSEcCtD
Phenylephrine—Rash—Orlistat—type 2 diabetes mellitus	0.000136	0.000787	CcSEcCtD
Phenylephrine—Paraesthesia—Ramipril—type 2 diabetes mellitus	0.000136	0.000787	CcSEcCtD
Phenylephrine—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000136	0.000786	CcSEcCtD
Phenylephrine—Headache—Orlistat—type 2 diabetes mellitus	0.000135	0.000782	CcSEcCtD
Phenylephrine—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000135	0.000781	CcSEcCtD
Phenylephrine—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000132	0.000768	CcSEcCtD
Phenylephrine—Dizziness—Metformin—type 2 diabetes mellitus	0.000131	0.000761	CcSEcCtD
Phenylephrine—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.00013	0.000756	CcSEcCtD
Phenylephrine—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.00013	0.000753	CcSEcCtD
Phenylephrine—Nausea—Valsartan—type 2 diabetes mellitus	0.000129	0.00075	CcSEcCtD
Phenylephrine—Nausea—Orlistat—type 2 diabetes mellitus	0.000128	0.000742	CcSEcCtD
Phenylephrine—Vomiting—Metformin—type 2 diabetes mellitus	0.000126	0.000732	CcSEcCtD
Phenylephrine—Rash—Metformin—type 2 diabetes mellitus	0.000125	0.000725	CcSEcCtD
Phenylephrine—Dermatitis—Metformin—type 2 diabetes mellitus	0.000125	0.000725	CcSEcCtD
Phenylephrine—Pruritus—Losartan—type 2 diabetes mellitus	0.000125	0.000723	CcSEcCtD
Phenylephrine—Headache—Metformin—type 2 diabetes mellitus	0.000124	0.000721	CcSEcCtD
Phenylephrine—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000124	0.000718	CcSEcCtD
Phenylephrine—Urticaria—Ramipril—type 2 diabetes mellitus	0.00012	0.000696	CcSEcCtD
Phenylephrine—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000119	0.00069	CcSEcCtD
Phenylephrine—Rash—Irbesartan—type 2 diabetes mellitus	0.000118	0.000685	CcSEcCtD
Phenylephrine—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000118	0.000684	CcSEcCtD
Phenylephrine—Nausea—Metformin—type 2 diabetes mellitus	0.000118	0.000683	CcSEcCtD
Phenylephrine—Headache—Irbesartan—type 2 diabetes mellitus	0.000117	0.00068	CcSEcCtD
Phenylephrine—Dizziness—Losartan—type 2 diabetes mellitus	0.000116	0.000676	CcSEcCtD
Phenylephrine—Vomiting—Losartan—type 2 diabetes mellitus	0.000112	0.00065	CcSEcCtD
Phenylephrine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000111	0.000646	CcSEcCtD
Phenylephrine—Nausea—Irbesartan—type 2 diabetes mellitus	0.000111	0.000645	CcSEcCtD
Phenylephrine—Rash—Losartan—type 2 diabetes mellitus	0.000111	0.000644	CcSEcCtD
Phenylephrine—Dermatitis—Losartan—type 2 diabetes mellitus	0.000111	0.000644	CcSEcCtD
Phenylephrine—Headache—Losartan—type 2 diabetes mellitus	0.00011	0.00064	CcSEcCtD
Phenylephrine—Epinephrine—CYP3A4—type 2 diabetes mellitus	0.000108	0.0224	CrCbGaD
Phenylephrine—Pruritus—Ramipril—type 2 diabetes mellitus	0.000107	0.00062	CcSEcCtD
Phenylephrine—Nausea—Losartan—type 2 diabetes mellitus	0.000105	0.000607	CcSEcCtD
Phenylephrine—Dizziness—Ramipril—type 2 diabetes mellitus	9.99e-05	0.000579	CcSEcCtD
Phenylephrine—Vomiting—Ramipril—type 2 diabetes mellitus	9.6e-05	0.000557	CcSEcCtD
Phenylephrine—Rash—Ramipril—type 2 diabetes mellitus	9.52e-05	0.000552	CcSEcCtD
Phenylephrine—Dermatitis—Ramipril—type 2 diabetes mellitus	9.51e-05	0.000552	CcSEcCtD
Phenylephrine—Headache—Ramipril—type 2 diabetes mellitus	9.46e-05	0.000549	CcSEcCtD
Phenylephrine—Nausea—Ramipril—type 2 diabetes mellitus	8.97e-05	0.00052	CcSEcCtD
Phenylephrine—ADRA1A—Signaling Pathways—EDNRB—type 2 diabetes mellitus	1.27e-05	0.000136	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—NCOA6—type 2 diabetes mellitus	1.27e-05	0.000136	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—PPARGC1A—type 2 diabetes mellitus	1.27e-05	0.000136	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.26e-05	0.000135	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.26e-05	0.000135	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—MTHFR—type 2 diabetes mellitus	1.25e-05	0.000135	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.25e-05	0.000134	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—HSD11B1—type 2 diabetes mellitus	1.25e-05	0.000134	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—UCP2—type 2 diabetes mellitus	1.25e-05	0.000134	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—UCP3—type 2 diabetes mellitus	1.25e-05	0.000134	CbGpPWpGaD
Phenylephrine—ADRA1A—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	1.23e-05	0.000132	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.23e-05	0.000132	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—AVP—type 2 diabetes mellitus	1.23e-05	0.000132	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.23e-05	0.000132	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.23e-05	0.000132	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—PPARA—type 2 diabetes mellitus	1.23e-05	0.000132	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.23e-05	0.000132	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.22e-05	0.000131	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.22e-05	0.000131	CbGpPWpGaD
Phenylephrine—ADRA1B—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.22e-05	0.000131	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling by GPCR—AGT—type 2 diabetes mellitus	1.21e-05	0.00013	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—APOB—type 2 diabetes mellitus	1.21e-05	0.00013	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.21e-05	0.00013	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—GCG—type 2 diabetes mellitus	1.2e-05	0.000129	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.2e-05	0.000129	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.2e-05	0.000129	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.19e-05	0.000128	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.19e-05	0.000128	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—AGT—type 2 diabetes mellitus	1.19e-05	0.000128	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—APOB—type 2 diabetes mellitus	1.19e-05	0.000128	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.18e-05	0.000127	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.18e-05	0.000127	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.18e-05	0.000126	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.17e-05	0.000126	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—PCK1—type 2 diabetes mellitus	1.17e-05	0.000126	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—CALM1—type 2 diabetes mellitus	1.17e-05	0.000126	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.17e-05	0.000126	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—APOE—type 2 diabetes mellitus	1.17e-05	0.000125	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.17e-05	0.000125	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.17e-05	0.000125	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—APOA1—type 2 diabetes mellitus	1.15e-05	0.000124	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—LPL—type 2 diabetes mellitus	1.15e-05	0.000124	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.15e-05	0.000124	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—LPL—type 2 diabetes mellitus	1.14e-05	0.000122	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—type 2 diabetes mellitus	1.13e-05	0.000121	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.12e-05	0.000121	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.12e-05	0.00012	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.11e-05	0.000119	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.1e-05	0.000119	CbGpPWpGaD
Phenylephrine—ADRA1B—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.1e-05	0.000118	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—HK1—type 2 diabetes mellitus	1.1e-05	0.000118	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—CD36—type 2 diabetes mellitus	1.1e-05	0.000118	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.09e-05	0.000117	CbGpPWpGaD
Phenylephrine—ADRA1A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.08e-05	0.000116	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—GCG—type 2 diabetes mellitus	1.07e-05	0.000115	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.07e-05	0.000115	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.07e-05	0.000114	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—HSD3B2—type 2 diabetes mellitus	1.06e-05	0.000114	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—LPA—type 2 diabetes mellitus	1.06e-05	0.000114	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—KCNJ11—type 2 diabetes mellitus	1.06e-05	0.000114	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—GCKR—type 2 diabetes mellitus	1.06e-05	0.000114	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.05e-05	0.000113	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.05e-05	0.000112	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.05e-05	0.000112	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.05e-05	0.000112	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.04e-05	0.000111	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—C3—type 2 diabetes mellitus	1.02e-05	0.00011	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—AVP—type 2 diabetes mellitus	1.02e-05	0.00011	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.02e-05	0.00011	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—type 2 diabetes mellitus	1.02e-05	0.000109	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.02e-05	0.000109	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—PPARG—type 2 diabetes mellitus	1.02e-05	0.000109	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—ALDOB—type 2 diabetes mellitus	1.02e-05	0.000109	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.01e-05	0.000109	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1e-05	0.000108	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	9.99e-06	0.000107	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—INS—type 2 diabetes mellitus	9.97e-06	0.000107	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—APOB—type 2 diabetes mellitus	9.87e-06	0.000106	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—type 2 diabetes mellitus	9.87e-06	0.000106	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.83e-06	0.000106	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	9.81e-06	0.000105	CbGpPWpGaD
Phenylephrine—ADRA1A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	9.8e-06	0.000105	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—HIF1A—type 2 diabetes mellitus	9.75e-06	0.000105	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—IRS2—type 2 diabetes mellitus	9.73e-06	0.000104	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—AGT—type 2 diabetes mellitus	9.72e-06	0.000104	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.72e-06	0.000104	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	9.67e-06	0.000104	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	9.56e-06	0.000103	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—CALM1—type 2 diabetes mellitus	9.55e-06	0.000103	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—LEP—type 2 diabetes mellitus	9.52e-06	0.000102	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—APOE—type 2 diabetes mellitus	9.52e-06	0.000102	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—GLP1R—type 2 diabetes mellitus	9.44e-06	0.000101	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—LPL—type 2 diabetes mellitus	9.43e-06	0.000101	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—APOA1—type 2 diabetes mellitus	9.41e-06	0.000101	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	9.28e-06	9.97e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.23e-06	9.91e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—GNB3—type 2 diabetes mellitus	9.2e-06	9.87e-05	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—ALB—type 2 diabetes mellitus	9.14e-06	9.82e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—MMP3—type 2 diabetes mellitus	9.07e-06	9.74e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—AVP—type 2 diabetes mellitus	9.07e-06	9.74e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—IGF2—type 2 diabetes mellitus	9.03e-06	9.7e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	8.99e-06	9.66e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.98e-06	9.64e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	8.9e-06	9.56e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.85e-06	9.5e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—SLC2A2—type 2 diabetes mellitus	8.82e-06	9.46e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—APOB—type 2 diabetes mellitus	8.77e-06	9.41e-05	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—PIK3R1—type 2 diabetes mellitus	8.75e-06	9.39e-05	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—NOS3—type 2 diabetes mellitus	8.75e-06	9.39e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	8.73e-06	9.38e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.69e-06	9.32e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CPT1A—type 2 diabetes mellitus	8.64e-06	9.27e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—MTR—type 2 diabetes mellitus	8.64e-06	9.27e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—EDN1—type 2 diabetes mellitus	8.63e-06	9.26e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—IRS1—type 2 diabetes mellitus	8.49e-06	9.12e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—C3—type 2 diabetes mellitus	8.49e-06	9.11e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—NAMPT—type 2 diabetes mellitus	8.47e-06	9.09e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	8.42e-06	9.04e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—GCK—type 2 diabetes mellitus	8.42e-06	9.04e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—LIPC—type 2 diabetes mellitus	8.42e-06	9.04e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—HBA1—type 2 diabetes mellitus	8.42e-06	9.04e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—LPL—type 2 diabetes mellitus	8.37e-06	8.99e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CYP11A1—type 2 diabetes mellitus	8.37e-06	8.98e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—SLC9A1—type 2 diabetes mellitus	8.22e-06	8.82e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.2e-06	8.8e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—INS—type 2 diabetes mellitus	8.13e-06	8.73e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CETP—type 2 diabetes mellitus	8.12e-06	8.72e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	8.09e-06	8.69e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—IRS2—type 2 diabetes mellitus	8.07e-06	8.67e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—AGT—type 2 diabetes mellitus	8.06e-06	8.66e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—CCL2—type 2 diabetes mellitus	8e-06	8.59e-05	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—PTGS2—type 2 diabetes mellitus	8e-06	8.59e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.93e-06	8.51e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—APOE—type 2 diabetes mellitus	7.9e-06	8.48e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—LEP—type 2 diabetes mellitus	7.9e-06	8.48e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.87e-06	8.45e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.86e-06	8.44e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	7.86e-06	8.43e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.83e-06	8.4e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.81e-06	8.39e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	7.72e-06	8.28e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	7.57e-06	8.13e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—PSMD6—type 2 diabetes mellitus	7.55e-06	8.1e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—SNAP25—type 2 diabetes mellitus	7.55e-06	8.1e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—SREBF1—type 2 diabetes mellitus	7.55e-06	8.1e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—C3—type 2 diabetes mellitus	7.54e-06	8.09e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.47e-06	8.02e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.45e-06	8e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CTGF—type 2 diabetes mellitus	7.41e-06	7.96e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	7.34e-06	7.88e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	7.24e-06	7.78e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.19e-06	7.72e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	7.19e-06	7.72e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.17e-06	7.7e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—AGT—type 2 diabetes mellitus	7.16e-06	7.69e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	7.13e-06	7.66e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—NOS3—type 2 diabetes mellitus	7.13e-06	7.66e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.05e-06	7.57e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.04e-06	7.56e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—APOE—type 2 diabetes mellitus	7.02e-06	7.54e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—LEP—type 2 diabetes mellitus	7.02e-06	7.54e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	6.94e-06	7.45e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	6.9e-06	7.41e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	6.83e-06	7.33e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—INS—type 2 diabetes mellitus	6.75e-06	7.25e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—RELA—type 2 diabetes mellitus	6.71e-06	7.21e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	6.66e-06	7.15e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.64e-06	7.13e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	6.62e-06	7.11e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.62e-06	7.11e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	6.55e-06	7.03e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	6.55e-06	7.03e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.53e-06	7.01e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.52e-06	7e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.5e-06	6.98e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.26e-06	6.72e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.2e-06	6.66e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.11e-06	6.56e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.06e-06	6.5e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.02e-06	6.46e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—INS—type 2 diabetes mellitus	6e-06	6.44e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.92e-06	6.36e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.92e-06	6.36e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.9e-06	6.33e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.8e-06	6.23e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.8e-06	6.22e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.77e-06	6.2e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.72e-06	6.14e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.66e-06	6.08e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	5.64e-06	6.06e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.64e-06	6.06e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	5.62e-06	6.03e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—RELA—type 2 diabetes mellitus	5.57e-06	5.98e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.55e-06	5.96e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	5.54e-06	5.95e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.51e-06	5.91e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	5.38e-06	5.77e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—SRC—type 2 diabetes mellitus	5.28e-06	5.66e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.26e-06	5.65e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.26e-06	5.65e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	5.23e-06	5.62e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.14e-06	5.52e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	5.14e-06	5.51e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.07e-06	5.45e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	5.03e-06	5.4e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.03e-06	5.4e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	5.01e-06	5.38e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.99e-06	5.36e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	4.95e-06	5.31e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	4.88e-06	5.24e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	4.82e-06	5.17e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.75e-06	5.1e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.72e-06	5.06e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.7e-06	5.04e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	4.62e-06	4.96e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.62e-06	4.96e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.61e-06	4.95e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	4.54e-06	4.87e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.51e-06	4.84e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.46e-06	4.79e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.44e-06	4.76e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	4.39e-06	4.72e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—SRC—type 2 diabetes mellitus	4.38e-06	4.7e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	4.32e-06	4.64e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	4.31e-06	4.62e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.27e-06	4.58e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	4.26e-06	4.57e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.22e-06	4.53e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.17e-06	4.48e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.09e-06	4.39e-05	CbGpPWpGaD
Phenylephrine—MAOA—Metabolism—AKT1—type 2 diabetes mellitus	4.02e-06	4.32e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.91e-06	4.2e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	3.89e-06	4.18e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.84e-06	4.12e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.79e-06	4.07e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	3.75e-06	4.03e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	3.68e-06	3.95e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—IL6—type 2 diabetes mellitus	3.55e-06	3.82e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.48e-06	3.73e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.41e-06	3.66e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	3.37e-06	3.62e-05	CbGpPWpGaD
Phenylephrine—ADRA1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.28e-06	3.52e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	3.23e-06	3.46e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	3.23e-06	3.46e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	2.95e-06	3.17e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—IL6—type 2 diabetes mellitus	2.95e-06	3.17e-05	CbGpPWpGaD
Phenylephrine—ADRA1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.72e-06	2.92e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.62e-06	2.81e-05	CbGpPWpGaD
Phenylephrine—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.42e-06	2.59e-05	CbGpPWpGaD
Phenylephrine—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	1.48e-06	1.59e-05	CbGpPWpGaD
